Loading...
10 regdanvimab COVID-19 controlled studies, 2 RCTs
64% improvement
for early treatment, RR
0.36
[0.26-0.52]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lee
59%
0.41 [0.02-10.1]
death
0/234
1/544
Improvement, RR [CI]
Treatment
Control
Lee (PSM)
82%
0.18 [0.06-0.52]
severe case
234 (n)
234 (n)
Lee (PSM)
45%
0.55 [0.30-1.00]
oxygen
234 (n)
234 (n)
Lee
8%
0.92 [0.87-0.97]
no disch.
234 (n)
544 (n)
Lee
77%
0.23 [0.09-0.58]
no disch.
5/234
50/544
Streinu-.. (DB RCT)
-151%
2.51 [0.10-61.1]
ventilation
1/203
0/104
Streinu-.. (DB RCT)
54%
0.46 [0.18-1.15]
oxygen
8/203
9/104
Streinu-.. (DB RCT)
49%
0.51 [0.21-1.25]
hosp.
9/203
9/104
Streinu-.. (DB RCT)
49%
0.51 [0.21-1.25]
progression
9/203
9/104
Streinu-.. (DB RCT)
35%
0.65 [0.49-0.86]
recov. time
203 (n)
104 (n)
Streinu-.. (DB RCT)
2%
0.98 [0.81-1.20]
viral time
203 (n)
104 (n)
Chae
71%
0.29 [0.01-5.76]
death
0/25
2/99
Chae
64%
0.36 [0.05-2.66]
ventilation
1/25
11/99
Chae
9%
0.91 [0.68-1.23]
hosp. time
25 (n)
99 (n)
Park (PSM)
79%
0.21 [0.12-0.34]
progression
19/377
81/377
Park (PSM)
13%
0.87 [0.83-0.91]
hosp. time
377 (n)
377 (n)
Jang
60%
0.40 [0.26-0.63]
oxygen
17/73
79/137
Jang
44%
0.56 [0.33-0.94]
no disch.
14/73
47/137
Jang
35%
0.65 [0.50-0.85]
no disch.
34/73
98/137
Jang
13%
0.87 [0.79-0.96]
hosp. time
73 (n)
137 (n)
Kim (DB RCT)
50%
0.50 [0.05-5.53]
death
1/656
2/659
Kim (DB RCT)
86%
0.14 [0.01-2.77]
ventilation
0/656
3/659
Kim (DB RCT)
91%
0.09 [0.01-1.64]
ICU
0/656
5/659
Kim (DB RCT)
69%
0.31 [0.17-0.54]
oxygen
15/656
49/659
Kim (DB RCT)
69%
0.31 [0.18-0.54]
hosp.
16/656
52/659
Kim (DB RCT)
70%
0.30 [0.18-0.52]
progression
16/656
53/659
Kim (DB RCT)
72%
0.28 [0.16-0.51]
progression
14/446
48/434
Kim (DB RCT)
32%
0.68 [0.60-0.77]
viral+
612 (n)
618 (n)
Jang
70%
0.30 [0.01-7.25]
death
0/418
1/304
Jang
12%
0.88 [0.84-0.92]
hosp. time
418 (n)
304 (n)
Jang
49%
0.51 [0.41-0.64]
oxygen
92/418
130/304
Jang
68%
0.32 [0.22-0.48]
no disch.
31/418
70/304
Kim
51%
0.49 [0.34-0.71]
progression
1,095 (n)
1,119 (n)
Kim
34%
0.67 [0.35-1.27]
progression
1,095 (n)
1,119 (n)
Kim
32%
0.68 [0.56-0.82]
oxygen
1,095 (n)
1,119 (n)
Kim
4%
0.96 [0.70-1.33]
oxygen
1,095 (n)
1,119 (n)
Hwang
83%
0.17 [0.02-1.37]
death
1/189
6/189
Hwang
92%
0.08 [0.01-0.78]
death
0/189
6/189
Hwang
0%
1.00 [0.06-15.9]
ventilation
1/189
1/189
Hwang
33%
0.67 [0.28-1.59]
ICU
8/189
12/189
Hwang
55%
0.45 [0.25-0.82]
oxygen
14/189
31/189
Choi
86%
0.14 [0.01-2.56]
death
0/65
5/333
Choi
76%
0.24 [0.07-0.60]
oxygen
4/65
67/333
Regdanvimab COVID-19 outcomes
c19 early .org
May 2024
Favors regdanvimab
Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit